Premium
Evaluation of the plasma concentration of ponatinib in a chronic myeloid leukaemia patient with ponatinib intolerance
Author(s) -
Abumiya Maiko,
Takahashi Naoto,
Yoshioka Tomoko,
Kameoka Yoshihiro,
Miura Masatomo
Publication year - 2021
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.13257
Subject(s) - ponatinib , medicine , bioavailability , chronic myeloid leukaemia , adverse effect , tyrosine kinase inhibitor , pharmacology , myeloid leukemia , tyrosine kinase , drug , nilotinib , imatinib , cancer , receptor
What is known and objective Some patients with chronic myeloid leukaemia (CML) cannot continue tyrosine kinase inhibitor (TKI) treatment due to intolerance associated with higher plasma concentration. Case summary A 76‐year‐old woman with chronic‐phase CML who showed resistance/intolerance to pre‐TKIs has been treated with ponatinib. A high ponatinib bioavailability was noted; therefore, we administered ponatinib 15 mg/3 d to avoid adverse events due to high exposure. Eventually, the patient achieved a major molecular response. What is new and conclusion Monitoring of the ponatinib plasma concentration led to safe and effective CML management in a patient with higher drug bioavailability.